论文部分内容阅读
ＡｓｔｒａＺｅｎｅｃａ公司针对糖尿病患者的高血压进行研究，从而进一步拓展了血管紧张素Ⅱ抑制剂坎地沙坦的临床应用。 降低Ⅱ型糖尿病患者的血压可减少并发症，改善存活率。世界卫生组织和国际高血压协会建议糖尿病患者的血压应控制在１７．３３／１１．３３ｋＰａ以下。
AstraZeneca company for the study of hypertension in diabetic patients, thus further expanding the clinical application of candesartan angiotensin Ⅱ inhibitor. Reduce blood pressure in patients with type 2 diabetes can reduce complications and improve survival. WHO and the International Society of Hypertension suggest that the blood pressure of diabetic patients should be controlled below 17.33 / 11.33kPa.